Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes - PubMed (original) (raw)
Review
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
Caroline K Kramer et al. Annu Rev Med. 2019.
Abstract
Clinical studies evaluating the cardiovascular safety/impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors demonstrated a reduction in major adverse cardiovascular events driven primarily by a reduced cardiovascular mortality in individuals with type 2 diabetes and previous cardiovascular disease. These somewhat unexpected results are coupled with SGLT-2 inhibitors' known acute effect of improvement in glycemia, reduction in blood pressure, and weight loss. In this review, we summarize the mechanism of action of SGLT-2 inhibitors, the metabolic effects of this class of medication, and the remarkable results of cardiovascular safety trials. In addition, we discuss adverse effects associated with these medications and the current recommendations for the use of these agents in the management of diabetes.
Keywords: SGLT-2; T2DM; cardiovascular disease; glucose lowering; sodium–glucose cotransporter–2 inhibitors; type 2 diabetes mellitus.
Similar articles
- The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V, Connelly K, Lin P, McFarlane P. Woo V, et al. Curr Med Res Opin. 2019 Jul;35(7):1283-1295. doi: 10.1080/03007995.2019.1576479. Epub 2019 Feb 15. Curr Med Res Opin. 2019. PMID: 30767677 Review. - Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.
Imprialos KP, Stavropoulos K, Stavropoulos N, Patoulias D, Petidis K, Grassos C, Dimitriadis K, Tsioufis C. Imprialos KP, et al. Cardiovasc Hematol Disord Drug Targets. 2018;18(2):104-113. doi: 10.2174/1871529X18666180206144342. Cardiovasc Hematol Disord Drug Targets. 2018. PMID: 29412121 Review. - SGLT-2 Inhibitors: Fighting Cardiovascular Disease Mortality in Diabetes.
Ghaffar ZA, Anwar S, Rizvi SW. Ghaffar ZA, et al. J Coll Physicians Surg Pak. 2019 Feb;29(2):195. doi: 10.29271/jcpsp.2019.02.195. J Coll Physicians Surg Pak. 2019. PMID: 30700368 No abstract available. - Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
Bonaventura A, Carbone S, Dixon DL, Abbate A, Montecucco F. Bonaventura A, et al. J Intern Med. 2019 Jul;286(1):16-31. doi: 10.1111/joim.12890. Epub 2019 Mar 19. J Intern Med. 2019. PMID: 30888088 Review. - SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
Santos-Ferreira D, Gonçalves-Teixeira P, Fontes-Carvalho R. Santos-Ferreira D, et al. Cardiology. 2020;145(5):311-320. doi: 10.1159/000504694. Epub 2019 Dec 20. Cardiology. 2020. PMID: 31865310 Review.
Cited by
- Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis.
Chen HF, Chang YH, Lo HJ, Isfandiari MA, Martini S, Hou WH, Li CY. Chen HF, et al. Cardiovasc Diabetol. 2020 Oct 14;19(1):177. doi: 10.1186/s12933-020-01144-y. Cardiovasc Diabetol. 2020. PMID: 33054769 Free PMC article. - Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.
González-Albarrán O, Morales C, Pérez-Maraver M, Aparicio-Sánchez JJ, Simó R. González-Albarrán O, et al. Diabetes Ther. 2022 Jul;13(Suppl 1):35-49. doi: 10.1007/s13300-022-01276-2. Epub 2022 Jun 15. Diabetes Ther. 2022. PMID: 35704167 Free PMC article. Review. - Polyphenolic Compounds in Fabaceous Plants with Antidiabetic Potential.
Guerrero-Becerra L, Morimoto S, Arrellano-Ordoñez E, Morales-Miranda A, Guevara-Gonzalez RG, Feregrino-Pérez AA, Lomas-Soria C. Guerrero-Becerra L, et al. Pharmaceuticals (Basel). 2025 Jan 9;18(1):69. doi: 10.3390/ph18010069. Pharmaceuticals (Basel). 2025. PMID: 39861134 Free PMC article. Review. - Coronary Microvascular Dysfunction.
Vancheri F, Longo G, Vancheri S, Henein M. Vancheri F, et al. J Clin Med. 2020 Sep 6;9(9):2880. doi: 10.3390/jcm9092880. J Clin Med. 2020. PMID: 32899944 Free PMC article. Review. - Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial.
Yang X, He Z, Yuan L, Huang W, Li D, Xiang P, Chen Y, Chen G, Liu C. Yang X, et al. BMC Endocr Disord. 2023 Oct 10;23(1):215. doi: 10.1186/s12902-023-01461-9. BMC Endocr Disord. 2023. PMID: 37814256 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical